Skip to main navigation Skip to search Skip to main content

Revisiting COX-2 inhibitors for Alzheimer's disease as multitargeted ligands: Development of 4-hydrazono-pyrazolidinediones with tuned COX selectivity profile and improved cellular potency

  • Reham Waheed
  • , Zeinab Mostafa
  • , Michael Emad
  • , Sarah S. Darwish
  • , Rosa Purgatorio
  • , Daniela Valeria Miniero
  • , Annalisa De Palma
  • , Tzu Peng Cheng
  • , Ting Yu Wang
  • , Yu Cheng Chen
  • , Ahmed M. El Kerdawy
  • , Moustafa Gabr
  • , Marco Catto
  • , Ashraf H. Abadi
  • , Tsong Long Hwang*
  • , Mohammad Abdel-Halim*
  • *Corresponding author for this work
  • German University in Cairo
  • University of Hertfordshire Hosted by Global Academic Foundation
  • University of Bari
  • 'Giuseppe Degennaro' LUM University
  • Chang Gung University
  • Kaohsiung Medical University
  • Chang Gung University of Science and Technology
  • University of Lincoln
  • Cairo University
  • Cornell University

Research output: Contribution to journal › Journal Article › peer-review

1 Scopus citations

Abstract

Herein, we expand on our previously synthesized 4-hydrazono-pyrazolidinedione COX-2 inhibitors as multitargeted agents for Alzheimer's disease (AD). Structural modifications of the 4-phenylhydrazono group led to the identification of several highly potent COX-2 inhibitors, with compound 3 exhibiting the strongest COX-2 inhibition (IC50 = 0.07 μM), with a balanced COX-2/COX-1 profile, suggesting lower cardiovascular risk. Compounds 2 and 9 showed high potency and selectivity shift toward COX-1 and displayed strong antiplatelet activity. Several derivatives showed 4–7 times improved submicromolar cellular potency, significantly inhibiting PGE2 release in LPS-stimulated THP-1 cells. Compounds 2, 3, 7, and 9 maintained the multitarget profile and inhibited Aβ and tau aggregation. Compounds 2, 3, and 7 protected against Amyloid-beta (Aβ)- and H2O2-induced cytotoxicity, confirming their neuroprotective activity with high potential for BBB permeability demonstrated via PAMPA and MDCK-MDR1 assays. These results support the potential of multitargeted COX-2 inhibitors as AD therapeutics and suggest a re-evaluation of their role in neurodegenerative disease treatment.

Original languageEnglish
Article number118261
JournalEuropean Journal of Medicinal Chemistry
Volume302
DOIs
StatePublished - 15 01 2026

Bibliographical note

Publisher Copyright:
© 2025 Elsevier Masson SAS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alzheimer's disease
  • COX-2 inhibitors
  • Multitargeted ligands

Fingerprint

Dive into the research topics of 'Revisiting COX-2 inhibitors for Alzheimer's disease as multitargeted ligands: Development of 4-hydrazono-pyrazolidinediones with tuned COX selectivity profile and improved cellular potency'. Together they form a unique fingerprint.

Cite this